Physician profile
Ronald Gonzalez
NPI 1639277528
$10,390.67
in general payments reported to CMS, 2019-2025
24 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what 93% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $383 · 2021: $1,552 · 2022: $1,824 · 2023: $1,588 · 2024: $2,122 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,583.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,641.66 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Nevro Corp. | $1,639.84 | 2020-2024 | Senza |
| Amgen INC. | $1,234.73 | 2019-2023 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $798.40 | 2022-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $583.38 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $513.88 | 2021 | |
| Novo Nordisk INC | $431.95 | 2021-2024 | |
| Axsome Therapeutics, INC. | $358.42 | 2024-2025 | Auvelity, Symbravo |
| Abbvie INC. | $352.51 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $347.35 | 2021-2022 | |
| Globus Medical, INC. | $343.06 | 2025 | Senza |
| Lundbeck LLC | $124.99 | 2024 | Vyepti |
| Glaxosmithkline, LLC. | $124.79 | 2022 | |
| Amarin Pharma, INC. | $121.88 | 2019 | |
| Lilly USA, LLC | $119.42 | 2025 | Zepbound |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $117.44 | 2025 | |
| Boston Scientific Corporation | $104.34 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $92.32 | 2022 | |
| Allergan, INC. | $92.23 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.22 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.74 | 2020-2021 | |
| Biogen, INC. | $65.16 | 2022 | |
| Acera Surgical, INC. | $21.69 | 2024 | Restrata Wound Matrix |
| Biodelivery Sciences International, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.